

GLAUCOMA THERAPY QUESTIONNAIRE

Date: ____/____/____

Name: _____

Address: _____

Phone: _____ E-mail: _____

Have you been diagnosed with glaucoma or ocular hypertension (high eye pressure)?

- Yes No

How many glaucoma medications do you take per day?

- 0 1 2 3 More than 3

Do you ever forget to take your glaucoma medication?

- Sometimes, in the morning
 Sometimes, at night
 In the morning and at night
 Never

Approximately how much money do you spend on glaucoma medications per month?

- Less than \$10
 \$10 to \$25
 \$26 to \$50
 \$51 to \$100
 More than \$100


Are you interested in learning about in-office laser therapy that may reduce or eliminate your need to take glaucoma medications?

- Yes No

Please see reverse side for more information about Lumenis SLT glaucoma therapy, its indication, and the importance of eye pressure control. Information provided to you by Lumenis.

Do you ever forget to take your glaucoma medication?

You are not alone



More than 90% of glaucoma patients do not take their prescription eye drop medications regularly¹

- Information published in the *American Journal of Ophthalmology* from a study of over 5,000 patients with glaucoma

Why is controlling eye pressure important?

- High eye pressure is the number one risk factor for glaucoma²
- High eye pressure or large changes in eye pressure increases the risk for vision loss due to glaucoma^{3,4}
- Not taking glaucoma eye drop medications as they are prescribed by your doctor can cause large changes in eye pressure

How does Lumenis SLT control eye pressure?

- SLT is a convenient, in-office laser therapy
- The laser energy stimulates a natural response that results in an improvement in the outflow of fluid from the eye⁵
- The natural improvement in outflow decreases eye pressure
- SLT is clinically proven to reduce and provide long-term control of eye pressure⁶
- SLT may reduce or eliminate your need to take eye drop medications for glaucoma⁷

Ask Your Eye Doctor About

LUMENIS® SLT

Lumenis selective laser trabeculoplasty (SLT) for the reduction of intraocular pressure in patients with open-angle glaucoma.

Lumenis SLT is typically covered by Medicare when medically necessary



5302 Betsy Ross Drive Santa Clara, CA 95054 1.877.586.3647
www.opthalmic.lumenis.com | www.lumenis.com/slt

Lumenis and its logo are registered trademarks of Lumenis Ltd. CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. Product specifications are subject to change without notice. Copyright © 2008, the Lumenis group of companies. All rights reserved. PB-1022690 rev. A

1. Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. *Am J Ophthalmol.* 2005;140:598-606. 2. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. *Arch Ophthalmol.* 2002;120:701-713. 3. The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. *Am J Ophthalmol.* 2000;130:429-440. 4. Asrani S, Zeimer R, Wilensky J, Grieser D, Vitale S, Lindermuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. *J Glaucoma.* 2000;9:134-142. 5. Damji KF, Bovell AM, Hodge WG. Selective laser trabeculoplasty: a review and comparison to argon laser trabeculoplasty. *Ophthalmic Pract.* 2003;21:54-58. 6. Melamed S, Ben Simon GJ, Levkovitch-Verbin H. Selective laser trabeculoplasty as primary treatment for open-angle glaucoma. *Arch Ophthalmol.* 2003;121:957-960. 7. Francis BA, Ianchulev T, Schofield JK, Minckler DS. Selective laser trabeculoplasty as a replacement for medical therapy in open-angle glaucoma. *Am J Ophthalmol.* 2005;140:524-525.